Titan Bio Tech Ltd Stock Price Today (NSE: TITANBIO)
Fundamental Score
Titan Bio Tech Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Titan Bio Tech Ltd share price today is ₹306.75, up +0.00% on NSE/BSE as of 20 February 2026. Titan Bio Tech Ltd (TITANBIO) is a Small-cap company in the Specialty Chemicals sector with a market capitalisation of ₹820.38 (Cr). The 52-week high for TITANBIO share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 35.58x, TITANBIO is currently trading above its industry average P/E of 29.20x. The company has a Return on Equity (ROE) of 15.01% and a debt-to-equity ratio of 0.05.
Titan Bio Tech Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Titan Bio Tech Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Titan Bio Tech Share Price: Financial Stability Analysis
The specialty chemicals sector, a critical component of modern manufacturing, is experiencing heightened volatility due to fluctuating raw material costs and evolving environmental regulations. Understanding the financial stability of individual companies within this landscape is paramount for investors. This analysis examines the financial health of Titan Bio Tech Ltd, focusing on key metrics and comparing them to its peers. Currently, the Titan Bio Tech share price stands at ₹1014.200012. This assessment is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra.
Titan Bio Tech's Price-to-Earnings (PE) ratio is 35.58. This suggests that the market has high expectations for the company's future earnings growth. To put this in perspective, it's crucial to compare this valuation with its sector peers such as
Amal, Bhatia Colour, and Deep Polymers. While a higher PE ratio isn't inherently negative, it necessitates a deeper dive into the company's fundamentals to justify the premium. For example, a comparison to Amal may reveal differences in management quality, impacting investor confidence and thus, valuation multiples.Return on Capital Employed (ROCE) is a key indicator of profitability and efficiency. Titan Bio Tech boasts an ROCE of 16.9%. This figure represents the return the company generates from its capital investments. A consistently high ROCE, like the 16.9% Titan Bio Tech currently has, helps strengthen a company's economic moat. A higher ROCE implies the company is efficient in capital utilization and can reinvest profits at high rates of return, thus further solidifying its competitive advantage.
While the current Titan Bio Tech share price reflects investor sentiment, a sustainable long-term valuation requires the company to maintain healthy profitability metrics. The observed PE ratio and ROCE, combined with an awareness of the evolving dynamics of the specialty chemicals sector, allow for a considered perspective on its financial standing.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Titan Bio Tech Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of TITANBIO across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (15.01%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (16.90%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (22.83%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (36.25%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (14.52% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (26.47% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (26.47% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.05)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (43.26x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹54.58 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (55.78%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 0.03%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Titan Bio Tech Ltd Financial Statements
Comprehensive financial data for Titan Bio Tech Ltd including income statement, balance sheet and cash flow
About TITANBIO (Titan Bio Tech Ltd)
Titan Bio Tech Ltd (TITANBIO) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Specialty Chemicals sector with a current market capitalisation of ₹820.38 (Cr). Titan Bio Tech Ltd has delivered a Return on Equity (ROE) of 15.01% and a ROCE of 16.90%. The debt-to-equity ratio stands at 0.05, reflecting the company's capital structure. Investors tracking TITANBIO share price can monitor key metrics including P/E ratio, promoter holding of 55.78%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
TITANBIO Share Price: Frequently Asked Questions
What is the current share price of Titan Bio Tech Ltd (TITANBIO)?
As of 20 Feb 2026, 06:25 am IST, Titan Bio Tech Ltd share price is ₹306.75. The TITANBIO stock has a market capitalisation of ₹820.38 (Cr) on NSE/BSE.
Is TITANBIO share price Overvalued or Undervalued?
TITANBIO share price is currently trading at a P/E ratio of 35.58x, compared to the industry average of 29.20x. Based on this relative valuation, the Titan Bio Tech Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of TITANBIO share price?
The 52-week high of TITANBIO share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Titan Bio Tech Ltd share price?
Key factors influencing TITANBIO share price include quarterly earnings growth (Sales Growth: 36.25%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Titan Bio Tech Ltd a good stock for long-term investment?
Titan Bio Tech Ltd shows a 5-year Profit Growth of 26.47% and an ROE of 15.01%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.05 before investing in TITANBIO shares.
How does Titan Bio Tech Ltd compare with its industry peers?
Titan Bio Tech Ltd competes with major peers in the Specialty Chemicals. Investors should compare TITANBIO share price P/E of 35.58x and ROE of 15.01% against the industry averages to determine competitive standing.
What is the P/E ratio of TITANBIO and what does it mean?
TITANBIO share price has a P/E ratio of 35.58x compared to the industry average of 29.20x. Investors pay ₹36 for every ₹1 of annual earnings.
How is TITANBIO performing according to Bull Run's analysis?
TITANBIO has a Bull Run fundamental score of 61.09999999999999/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does TITANBIO belong to?
TITANBIO operates in the Specialty Chemicals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Titan Bio Tech Ltd share price.
What is Return on Equity (ROE) and why is it important for TITANBIO?
TITANBIO has an ROE of 15.01%, which indicates excellent management efficiency. ROE measures how efficiently Titan Bio Tech Ltd generates profits from shareholders capital.
How is TITANBIO debt-to-equity ratio and what does it indicate?
TITANBIO has a debt-to-equity ratio of 0.05, which indicates conservative financing with low financial risk.
What is TITANBIO dividend yield and is it a good dividend stock?
TITANBIO offers a dividend yield of 0.20%, meaning you receive ₹0.20 annual dividend for every ₹100 invested in Titan Bio Tech Ltd shares.
How has TITANBIO share price grown over the past 5 years?
TITANBIO has achieved 5-year growth rates of: Sales Growth 14.52%, Profit Growth 26.47%, and EPS Growth 26.47%.
What is the promoter holding in TITANBIO and why does it matter?
Promoters hold 55.78% of TITANBIO shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Titan Bio Tech Ltd.
What is TITANBIO market capitalisation category?
TITANBIO has a market capitalisation of ₹820 crores, placing it in the Small-cap category.
How volatile is TITANBIO stock?
TITANBIO has a beta of N/A. A beta > 1 suggests the Titan Bio Tech Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is TITANBIO operating profit margin trend?
TITANBIO has a 5-year average Operating Profit Margin (OPM) of 22.83%, indicating the company's operational efficiency.
How is TITANBIO quarterly performance?
Recent quarterly performance shows Titan Bio Tech Ltd YoY Sales Growth of 36.25% and YoY Profit Growth of 15.82%.
What is the institutional holding pattern in TITANBIO?
TITANBIO has FII holding of 0.00% and DII holding of 0.03%. Significant institutional holding often suggests professional confidence in the Titan Bio Tech Ltd stock.